Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03718104 · ClinicalTrials.gov registry record

MOM NEST Study: Maternal Opioid Medication: Naltrexone Efficacy Study

A clinical trial of Opioid Use Disorder and Alcohol Use Disorder, sponsored by Boston Medical Center.

Completed
Registry status
46
Enrollment target
2
Study locations

NCT03718104: Completed study of Opioid Use Disorder and Alcohol Use Disorder, sponsored by Boston Medical Center.

NCT03718104 is a study of Opioid Use Disorder and Alcohol Use Disorder that has completed, run by Boston Medical Center. The registered enrollment target is 46 participants, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03718104, a study of Opioid Use Disorder and Alcohol Use Disorder, has completed, sponsored by Boston Medical Center.

COMPLETED
Registry status
46 participants
Enrollment target
2
Study locations

Study Summary

This is a multi-center prospective comparative cohort study examining the safety, efficacy, pharmacokinetics, and pharmacogenomics of naltrexone for pregnant women with opioid use disorder. Pregnancy, delivery, and maternal and infant outcomes to 12 months post-delivery will be examined and compared with a cohort treated with buprenorphine/naloxone.

Primary Outcome

Maternal relapse of illicit and/or unprescribed drug use from maternal/provider report and or from urine toxicology testing at any point during the pregnancy and up to 12 months after delivery

Interventions

  • OTHER Pharmacokinetic analysis
  • OTHER Safety and Efficacy
  • GENETIC Genetic and epigenetic analysis
  • OTHER Breast milk analysis

Study Locations (2)

Massachusetts

  • Boston Medical Center - Boston

North Carolina

  • University of North Carolina Chapel Hill - Carrboro

Trial Details

FieldValue
Enrollment Target 46 participants
Start Date 2018-12-01
Est. Completion 2024-05-08
Boston Medical Center

253 total trials

What the finished NCT03718104 record still lists

NCT03718104 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (99% lower).

The record links to 4 conditions, with Opioid Use Disorder appearing as the primary indexed condition, and to 4 interventions - of which Pharmacokinetic analysis is the first listed.

NCT03718104 reports a single indexed study location in Massachusetts, North Carolina.

Frequently Asked Questions

What is clinical trial NCT03718104 about?

NCT03718104 is a clinical study titled "MOM NEST Study: Maternal Opioid Medication: Naltrexone Efficacy Study". This is a multi-center prospective comparative cohort study examining the safety, efficacy, pharmacokinetics, and pharmacogenomics of naltrexone for pregnant women with opioid use disorder. Pregnancy, delivery, and maternal and infant outcomes to 12 months post-delivery will be examined and compared...

What is the current status of trial NCT03718104?

This trial is currently completed. The enrollment target is 46 participants. The study started on 2018-12-01. Estimated completion is 2024-05-08.

What conditions does trial NCT03718104 study?

This clinical trial studies the following conditions: Opioid Use Disorder, Alcohol Use Disorder, Pregnancy, High Risk, Neonatal Abstinence Syndrome.

What interventions are being tested in trial NCT03718104?

The interventions under investigation include: Pharmacokinetic analysis (OTHER), Safety and Efficacy (OTHER), Genetic and epigenetic analysis (GENETIC), Breast milk analysis (OTHER).

Who is sponsoring clinical trial NCT03718104?

This trial is sponsored by Boston Medical Center, which has 253 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03718104 being conducted?

This trial has 2 study locations across Massachusetts, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Opioid Use Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03718104's enrollment target sits among peer trials

46 180th of 257 higher than 77 of 257 other Opioid Use Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Opioid Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01890590 · 46 participants · NA

    A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma

  • NCT03191149 · 46 participants · Phase 2

    Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

  • NCT03510208 · 46 participants · Phase 1

    Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery

  • NCT04048278 · 46 participants · Early Phase 1

    Lidocaine Infusion in Pancreatic Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03718104, the US trial registry maintained by the National Library of Medicine. NCT03718104 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.